We are an international network of healthcare professionals, researchers and consumers producing systematic reviews of evidence for treating cystic fibrosis and other genetic disorders (haemoglobinopathies. coagulopathies and inborn errors of metabolism). Our editorial base is located in Liverpool, UK.
If you are interested in working with us, please go to Join Cochrane. If you are already a member, please and take a look at our vacant priority titles.
|We have just published the first systematic review which includes evidence for the new triple therapies for people with CF over 12 years of age who have at least one copy of the F508del gene variant. In this updated review, Professor Kevin Southern and his author team have assessed and presented the evidence from a total of 19 randomised controlled trials of different corrector therapies which recruited 2959 participants worldwide. Previously presenting evidence from monotherapy and dual therapies, this updated version of the review now includes triple therapies. Three trials of the triple therapy known as Kaftrio™ in the UK (Trikafta™ in North America), and lasting from one to six months, present results for 633 people who took part in the trials. Professor Southern has described this new therapy as “transformative” for those who are eligible, with significant improvements in clinical outcomes, such as lung function and quality of life scores with few accompanying side effects. You can read the full review here and the plain language summary here.|
|Latest output published on The Cochrane Library|
|On Issue 2 2021 of The Cochrane Library we have published a total of 196 reviews and 22 protocols. There are also 9 registered titles currently progressing to protocol status. The production of these reviews involves a network of over 1000 contributors (authors, consumers and referees) throughout the world. We very much welcome interest from new consumers, referees and potential reviewers. Further information can be obtained by contacting the group. |
|By getting involved in these priority setting partnerships you can help shape future research. We have already successfully been invovled in a priority setting partnership for CF and you can see the results here. A priority setting partnership was also undertaken and recently published. More information can be found here.|